Please assess the completion status of the following clinical trial:

Trial Title: Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Continuous chest pain that lasted \> 30 minutes within the preceding 12 hours~* ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG~* Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography~* Angiographically detected culprit coronary artery lesion deemed suitable for PCI~Exclusion Criteria:~* Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin~* Culprit lesion in saphenous vein graft~* TIMI grade II-III flow in IRA~* Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)~* Presence of left bundle branch block~* History of prior MI~* Mechanical ventilation or inotropic support

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
- 2 (Type: ACTIVE_COMPARATOR): Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).